Pages Menu
Twitter
Categories Menu

Posted by on Jan 30, 2019 in Neurology

Another Nail in the Coffin for Anti-Amyloid Development in Alzheimer’s

Another Nail in the Coffin for Anti-Amyloid Development in Alzheimer’s

Roche has pulled the plug on late-phase development for its anti-amyloid MAb crenezumab for Alzheimer’s, owing to an anticipated lack of clinical efficacy. Fierce Biotech has the story, including what this might mean for other diehard (some might say, foolhardy) developers of anti-amyloid agents for AD. We’re looking at you, Biogen.

bmartin (1130 Posts)

A native East Tennessean, Barbara Martin is a formerly practicing, board-certified neurologist who received her BS (psychology, summa cum laude) and MD from Duke University before completing her postgraduate training (internship, residency, fellowship) at the Hospital of the University of Pennsylvania in Philadelphia. She has worked in academia, private practice, medical publishing, drug market research, and continuing medical education (CME). For the last 3 years, she has worked in a freelance capacity as a medical writer, analyst, and consultant. Follow Dr. Barbara Martin on and Twitter.